1 From Vaccine to Pathogen: Modeling Sabin 2 Vaccine Virus Reversion and Evolutionary Epidemiology Wesley Wong^{1*}, Jillian Gauld^{1*}, Michael Famulare^{1*} 2 3 4 **Author Affiliations** 5 1. Institute for Disease Modeling, Global Good, Intellectual Ventures, Bellevue, WA, USA 6 * Currently employed at the Bill and Melinda Gates Foundation 7 8 **Corresponding Author** 9 Michael Famulare 10 Building IV, 3150 139th Ave SE, Bellevue, WA 98005 11 +1 (425) 691-3327 12 mfamulare@idmod.org 13 14 **Keywords**: 15 Sabin 2, cVDPV2, poliovirus, genetic reversion, evolution, modeling, vaccine 16 Classification: BIOLOGICAL SCIENCES: Evolution 17 **Author Contributions** 18 WW and MF were involved with model development, analysis, and interpretation. All authors were 19 involved with manuscript writing and interpretation. Correspondence and requests for materials should be 20 addressed to Michael Famulare. 21

23 Abstract

24	The oral poliovirus vaccines (OPV) are one of most effective disease eradication tools in public
25	health. However, the Sabin 2 vaccine strain can revert attenuation and cause outbreaks of circulating,
26	vaccine-derived poliovirus (cVDPV2) that are clinically indistinguishable from wild poliovirus (WPV).
27	Accurately assessing cVDP2 risk requires disentangling the complex interaction between epidemiology
28	and evolutionary biology. Here, we developed a Sabin 2 reversion model that simulates the reversion of
29	Sabin 2 to WPV based on the clinical differences in shedding duration and infectiousness between
30	individuals vaccinated with Sabin 2 and those infected with wild poliovirus. Genetic reversion is
31	informed by a canonical reversion pathway defined by three gatekeeper mutations (A481G, U2909C,
32	and U398C) and the accumulation of genetic load from deleterious nonsynonymous mutations. Our
33	model captures essential aspects of both phenotypic and molecular evolution and simulates
34	transmission using a multiscale transmission model that consolidates the relationships among immunity,
35	susceptibility, and transmission risk. We show that despite the rapid reversion of Sabin 2, cVDPV2
36	outbreaks can be controlled by maintaining high levels of population-level immunity and sanitation.
37	Supplementary immunization activities must maintain high vaccine coverage to prevent future cVDPV2
38	outbreaks in the targeted intervention zone, but declining global immunity against Sabin 2 makes them
39	increasingly risky to implement in poor sanitation regions regardless of historical immunization activity.
40	A combined strategy of assessing and improving sanitation levels in conjunction with high coverage
41	vaccination campaigns will limit future cVDPV2 emergence and spread.

42

43 Significance Statement

Since the withdrawal of the Sabin 2 oral poliovirus vaccine (OPV2), circulating vaccine-derived
 poliovirus outbreaks caused by the genetic reversion of Sabin 2 vaccine virus (cVDPV2) have been

46	increasing in frequency. The current strategies for combating cVDPV2 involve supplemental
47	immunization activities with monovalent Sabin 2 oral poliovirus (mOPV2), which can inadvertently seed
48	future cVDPV2 outbreaks. Accurately assessing future cVDPV2 outbreak risk following mass mOPV2
49	campaigns is critical poliovirus eradication efforts but must consider the interaction between genetic
50	reversion and epidemiological transmission. We developed an evolutionary epidemiology model to
51	integrate Sabin 2 genetic reversion and transmission into a single framework to evaluate their relative
52	contribution to cVDPV2 outbreaks and inform future intervention strategies.
53	

54 Introduction

55 Mass immunization with oral poliovirus vaccine (OPV) has led to a >99.99% drop in wild 56 poliovirus (WPV) cases (1) and the complete eradication of Type 2 and Type 3 WPV. The OPVs are highly 57 efficacious vaccines that confer long-lasting protective immunity (2). A curious feature of these vaccines 58 is that vaccinated individuals can shed and transmit vaccine virus. Vaccine transmission increases 59 population-level immunity but is problematic when viruses revert attenuation, resulting in circulating, 60 vaccine-derived poliovirus (cVDPV) capable of causing paralytic poliomyelitis cases clinically 61 indistinguishable from WPV (3). Following the eradication of Type 2 WPV, the Global Polio Eradication 62 Initiative coordinated the global withdrawal of Sabin 2 OPV (OPV2) from routine immunization 63 schedules (commonly referred to as the Switch) to prevent future sources of circulating, vaccine-derived 64 Type 2 poliovirus (cVDPV2) (1). 65 Despite the Switch, cVDPV2 outbreaks continue to be a pressing public health concern and have 66 emerged as a significant issue threatening global poliovirus eradication efforts (1, 4). Although OPV2 is 67 no longer used in routine immunization, monovalent OPV2 (mOPV2) vaccination campaigns are still

used as supplemental immunization activities (SIAs) to combat cVDPV2 outbreaks. cVDPV2 outbreaks

are now reported throughout the African continent, Pakistan, Afghanistan, China, Malaysia and the Philippines and 29% of the outbreaks in Africa have involved international spread (4, 5). Since the Switch, 126 mOPV2 campaigns utilizing more than 300 million doses of OPV2 have been implemented to control cVDPV2 outbreaks (6). These SIAs are estimated to be responsible for seeding over half of the cVDPV2 outbreaks observed since the Switch (6). Ensuring the future safety and efficacy of these SIA campaigns while minimizing the risk of seeding future cVDPV2 outbreaks is critical to the success of the poliovirus eradication initiative.

76 The Sabin 2 vaccine strain was derived from a wild-type isolate (P22/P712/56) passaged in 77 monkey kidney cells to achieve neurovirulence attenuation (7). However, identifying the genetic 78 mutations responsible for attenuation has been surprisingly complicated, in part because the progenitor 79 has not been fully sequenced and because P22/P712/56 is thought to be naturally attenuated relative to 80 other WPV strains (8). Despite this, phylogenetic analyses of whole genome sequences collected from 81 cVDPV2 outbreaks suggest a common evolutionary pathway to attenuation reversal (9). This pathway is 82 characterized by the rapid fixation three gatekeeper mutations, A481G, U2909C, and U398C, within the 83 first few weeks after vaccination (9, 10). All three mutations have previously been implicated as 84 molecular determinants of attenuation for Sabin 2 (11–14). A481G and U398C are noncoding mutations 85 that affect the stability of a 5' hairpin structure that mediates translation efficiency (13, 15, 16) and 86 U2909C is a nonsynonymous mutation in the VP1 capsid protein.

However, genetic reversion is not the sole determinant of cVDPV2 emergence. Environmental sewer samples have identified revertant strains in regions with no detectable cVDPV2 cases (17). In fact, vaccinated individuals can shed and transmit revertant viruses to other individuals (10, 18), but whether this results in clinically-detected cVDPV2 outbreaks depends on the epidemiological context. These cVDPV2 outbreaks are associated with regions with historically poor vaccination rates and low population-level immunity (6, 19). Thus, while Sabin 2 reversion is a prerequisite of cVDPV2 emergence,

93 whether it triggers a public health crisis depends on the interactions between genetic reversion and

94 local epidemiological conditions.

95	Mathematical models can be useful tools for assessing cVDPV2 emergence risk and
96	characterizing the evolutionary and epidemiological factors that allow cVDPV2 outbreaks to occur. We
97	developed an evolutionary-epidemiology model that simulates Sabin 2 reversion as it is transmitted in
98	an epidemiological model previously calibrated during an mOPV2 clinical trial performed in Matlab,
99	Bangladesh (20). The combined model allows us to assess the consequences of vaccine reversion in the
100	context of an actual epidemiological setting. By unifying evolutionary theory, population genetics, and
101	epidemiology into a single framework, our study provides a holistic understanding of cVDPV2
102	emergence as it relates to both genetic reversion and transmission.
103	
104	Results
105	Brief model structure overview
106	We previously developed agent-based multiscale epidemiology model designed to replicate

107 household community structure and Sabin 2 vaccine transmission during an mOPV2 clinical trial 108 performed in Matlab, Bangladesh (20, 21). Transmission is contact based and made heterogeneously 109 depending on household community structure membership (Figure 1A). Susceptibility is defined by a 110 dose-response model that determines the probability of infection given the strain-specific viral 111 infectiousness, the total viral exposure dose per contact, and the immunity of the recipient host. The 112 total viral exposure dose is determined by the viral shedding concentration of the infected individual 113 and the average fecal-oral dose per contact in the population. Immunity is defined by the OPV-114 equivalent antibody titer that determines infection probability. Individuals with low immunity upon

infection have longer shedding durations and higher viral shedding titers. Further details of the
epidemiology model are described elsewhere (21, 22).

117 Here, we developed and integrated a new Sabin 2 reversion model into the multiscale 118 epidemiology model. Sabin 2 evolution is modeled as a population of multiple viral lineages founded by 119 a Sabin 2 vaccine virus strain during vaccination. These viral lineages evolve independently and compete 120 for the limited availability of naïve or low-immunity individuals in the population. Phenotypic evolution 121 is driven by the reversion of three gatekeeper mutations (A481G, U2909C, and U398C) and the 122 accumulation of deleterious nonsynonymous mutations generated through mutation and purged 123 through selection or genetic drift (Figure 1B). We assume complete genetic reversion results in a viral 124 population whose average infectiousness and shedding duration is identical to those of WPV. Due to the 125 independent acquisition of mutations across different viruses and viral lineages, individual viruses have 126 different infectiousness and shedding duration phenotypes even after the three gatekeeper mutations 127 have reverted.

128 Simulating Sabin 2 molecular evolution

129 To inform molecular evolution, intra-host substitution rates for the three gatekeeper mutations 130 were based on estimates previously calculated from 241 Vp1 (viral protein 1) segments from Sabin-like 131 poliovirus collected during routine surveillance in Nigeria (10, 23). Nonsynonymous and synonymous 132 substitution rates were calibrated (SI Appendix) to a set of whole genome sequences and VP1 capsids 133 segments isolated from infections from confirmed Sabin 2, Sabin-like, vaccine-derived poliovirus (VDPV) 134 and cVDPV2 cases (Figure 2). One notable feature of poliovirus evolution is the discordance between 135 short-term evolution following vaccination and long-term evolution after prolonged circulation. Short-136 term evolution is dominated by the accumulation of nonsynonymous mutations, as evidenced by the 137 increased rate of nonsynonymous mutation accumulation in the whole genome sequences during the

first year of evolution (Figure 2B), the reduction in the ratio of nonsynonymous to synonymous
 mutations over time (Figure 2D), and the elevated dN/dS ratios of Sabin-like samples compared to
 cVDPV2 samples (Supplemental Figure 1).

141 We hypothesized that the difference between short-term and long-term evolution represents a 142 shift in the distribution of fitness effects for nonsynonymous mutations. Simulated nonsynonymous 143 mutations were divided into two categories: deleterious mutations that can cause a reduction in either 144 infectiousness or shedding duration, and neutral mutations that have no phenotypic effect. Each 145 category is associated with a different substitution rate and deleterious nonsynonymous mutations are 146 purged using a recombination-like process that mimics selection and intra-species recombination within 147 the host (SI Appendix). Deleterious nonsynonymous mutations dominate molecular evolution during the 148 first year of evolution while neutral nonsynonymous mutations dominate molecular evolution after 149 prolonged circulation (Figure 2E).

150 Simulating Sabin 2 reversion

151 Genotype-to-phenotype maps for shedding duration were generated by comparing the 152 shedding duration of naïve individuals vaccinated with Sabin 2 (median 30.3, average 36 days) with 153 those infected with WPV (median 40.3, average 48 days) (SI Appendix). Due to the rapid intra-host 154 fixation of the three gatekeeper mutations (Figure 3A), we assert that reversion during an infection 155 extends its shedding duration (Figure 3B). Prior to any intra-host evolution, the genotype-to-phenotype 156 map for shedding duration estimates that naïve individuals vaccinated with non-reverted Sabin 2 have a 157 median shedding duration of 13.5 days (Figure 3B, dashed red line). The clinically-observed shedding 158 durations of Sabin 2 vaccinated individuals (Figure 3B, solid red line) is realized as the average shedding 159 durations of different viral genotypes composed of unmutated and reverted Sabin 2 viruses 160 (Supplemental Table 1). After vaccination, 7.6% of simulated vaccinated individuals shed non-reverted

161	Sabin 2 at the end of shedding, 92.4% shed virus with at least one reverted gatekeeper mutation, and
162	35.2% shed virus with all three gatekeeper mutations reverted. Interestingly, we did not identify a
163	deleterious cost (reduction in shedding duration) associated with nonsynonymous mutation
164	accumulation (SI Appendix).
165	The genotype-to-phenotype map describing viral infectiousness was based on clinical
166	differences of human dose response between Sabin 2 and WPV. Unlike shedding duration, we identified
167	a small negative effect associated with deleterious nonsynonymous mutations resulting in a reduction in
168	viral infectiousness (SI Appendix). Our model predicts that viral genotypes with no deleterious
169	nonsynonymous mutations but are reverted at A481G and U2909C are more infectious than typical WPV
170	strains (Figure 3C). Each additional deleterious nonsynonymous mutation reduces infectiousness such
171	that a viral genotype with all three gatekeeper mutations reverted and nine deleterious mutations is as
172	infectious as WPV (Figure 3D).
173	
174	Examining the evolutionary epidemiology dynamics of Sabin 2 reversion
175	To explore how Sabin 2 reversion and transmission interact, we simulated transmission
176	following an mOPV2 campaign targeting 10% of children under five in a population with 10 times the
177	fecal-oral dose of Matlab (2.5e-6 grams per contact) five years after vaccination cessation (Figure 4).

178 These epidemics are cyclic (Figure 4A) and characterized by boom-bust cycles that eventually stabilize

179 within the first three years of transmission. Under these conditions, 10% of stochastic replicates failed to

180 establish stable, endemic transmission. These stochastic replicates failed after the initial expansion wave

- 181 collapsed (Supplemental Figure 2A). Should transmission recover, the epidemic rebounds and the
- proportion of individuals with no immunity (serum neutralizing antibody titer < 8) declines while the
- proportion of individuals with high immunity (serum neutralizing antibody titer > 256) increases (Figure

4B). Towards the end of the initial epidemic, the proportion of individuals with no immunity begin to
increase due to a combination of new births and the waning of pre-existing immunity and sets up the
conditions for the next wave of infections.

187 Complete Sabin 2 reversion (Figure 4C-D) occurred within the first 200 days of transmission. To 188 describe the evolutionary dynamics of the simulated viral population, we focused on the expected mean 189 (the average of the average) phenotype and the variance of the expected mean. While both shedding 190 duration and infectiousness converged to the WPV phenotype, shedding duration approached it 191 monotonically while infectiousness exceeded WPV during the first few months of transmission. The 192 expected means of both phenotypes were not sensitive to changes in infection number. However, the 193 variance of the expected mean fluctuated over time and was sensitive to epidemiological dynamics. This 194 variance was smallest at the onset of the epidemic when infection numbers were highest and biggest 195 around day 400 when infection number was the smallest. The variance of the expected mean was 196 inversely correlated with total infection number, but its magnitude also depended on the rate with 197 which the epidemic was increasing or decreasing over time (Figure 4, Supplemental Figure 3). 198 Surprisingly, complete Sabin 2 reversion does not guarantee stable transmission. The 199 simulations with observed transmission failure did not show a lack of evolutionary fitness: the simulated 200 viral populations in these simulations had infectiousness and shedding durations equivalent to or 201 exceeding that of WPV (Supplemental Figure 2B-C). 202 Population-level immunity and hygiene are major constraints of cVDPV2 emergence 203 We next utilized this model to simulate cVDPV2 emergence and understand risk. Our scenarios

included a point importation of an infant vaccinated with Sabin 2, and a mass vaccination campaign with
up to 80% coverage in children under five years of age. We explored scenarios with fecal oral doses
equal to, five times greater, and 10 times greater than Matlab (Figure 5). The fecal oral dose, combined

207	with the infection-specific, time-dependent viral shedding concentration per gram of stool (22),
208	determines the total exposure dose per infectious contact. cVDPV2 emergence was defined as an
209	outbreak significant enough to trigger a warning from passive routine surveillance efforts. However,
210	because surveillance is not currently simulated, we operationally define cVDPV2 emergence as a
211	simulation with sustained cVDPV2 transmission for at least three years.
212	We found zero risk of cVDPV2 emergence following a mass vaccination campaign (Figure 5A) or
213	point importation event (Figure 5D) in Matlab with its current fecal oral dose. However, cVDPV2
214	emergence is possible at higher fecal-oral doses. Under these conditions, cVDPV2 emergence risk
215	increases with time since vaccination, but is controlled within the community by higher vaccination
216	coverage. When the fecal-oral dose was five times that of Matlab (1.8e-6 grams per contact), all
217	vaccination campaigns and point importations immediately after vaccination cessation (year 0) had a
218	less than 0.05 chance of causing a cVDPV2 emergence (Figure 5B). Vaccination campaigns with less than
219	30% coverage in populations with more than three years of vaccination cessation had the highest risk of
220	cVDPV2 emergence, with an emergence rate between 20% and 30%. Following point importation,
221	cVDPV2 emergence risk rises from 0% immediately after cessation to 20% after five years of cessation
222	(Figure 5E).
223	When the fecal-oral dose was ten times that of Matlab (2.5e-6 grams per contact), high
224	vaccination coverage could not efficiently prevent cVDPV2 emergence (Figure 5C). Immediately after
225	vaccination cessation, simulations with high vaccination coverage (> 70% coverage) resulted in cVDPV2
226	emergence 40-50% of the time. All other scenarios had a greater than 60% chance of cVDPV2
227	emergence. This increases to a greater than 80% chance following a vaccination campaign with less than

228 30% coverage in populations with more than three years of vaccination cessation. cVDPV2 emergence

- risk following a point importation event increases sharply with time since vaccination (Figure 5F),
- 230 increasing from 5% immediately after cessation to 55% after five years of cessation.

231

232 Discussion

233 cVDPV2 outbreaks are serious public health dilemmas made possible by viral evolution and 234 exacerbated by epidemiological conditions. By unifying evolutionary and epidemiological theory into a 235 single framework, our model assesses cVDPV2 emergence risk in relation to changes in shedding 236 duration and infectiousness associated with vaccine reversion and the constraints to transmission 237 imposed by immunity, sanitation, and contact structure. To overcome the lack of direct transmission 238 measurements for Sabin 2 reversion intermediates, we generated genotype-to-phenotype maps for 239 shedding duration and viral infectiousness by relying on established molecular evolution and population 240 genetic theory.

241 Sabin 2 reversion can be viewed as an adaptive process where Sabin 2 must climb up a fitness 242 landscape to achieve the optimal, WPV-like phenotype. Within the poliovirus virology literature, Sabin 2 243 is commonly presented as a purely adaptive process where fixed mutations contribute positively to the 244 emergence of the WPV phenotype (24). However, it is unlikely that all fixed nonsynonymous mutations 245 are beneficial (25) and viruses must purge deleterious mutations to prevent Muller's Ratchet from 246 causing an irreversible decline in viral fitness (26, 27). Muller's ratchet can be avoided by engaging in 247 intra-species or inter-species recombination with Enterovirus C viruses (28) and by altering the 248 distribution of fitness effects (DOFE) for fixed mutations (29, 30). The latter is based on Fisher's 249 Geometric Model (FGM) of adaptive evolution, which predicts that mutations with large-phenotypic 250 effects are unlikely to fixate the closer an organism is to its fitness optimum. Our model incorporates 251 FGM by attributing large phenotypic effects to the gatekeeper mutations and specifying 252 nonsynonymous mutation rates so that early adaptive evolution is dominated by deleterious 253 nonsynonymous mutations while long-term evolution is dominated by neutral ones.

254 Interestingly, we failed to identify a deleterious cost associated with nonsynonymous mutations 255 and shedding duration but did identify one associated with nonsynonymous mutations and infectivity. 256 This finding suggests that there are differences between intra-host and inter-host selection. This could 257 reflect strong purifying selection induced by the highly competitive intra-host survival dynamics due to 258 high viral titers. Conversely, the deleterious cost associated with infectiousness could result from the 259 genetic drift induced by the severe sampling of viral genotypes during person-to-person transmission 260 (25, 31). Strong genetic drift could weaken the efficacy of purifying selection in removing deleterious 261 mutations associated with inter-host transmission, but more work is needed to assess differences in 262 inter- and intra-host selection. The phenotypes we modeled are the consolidation of multiple factors 263 such as cell invasion, replication, immune evasion, and environmental survival. These subfactors likely 264 contribute to both shedding duration and infectiousness, but our ability to map molecular evolution to 265 these subfactors remains limited.

266 At its core, cVDPV2 emergence is an evolutionary and epidemiological problem that requires a 267 combined approach to properly assess how the two interact. From an evolutionary perspective, the 268 availability of susceptible hosts and the distribution of transmissions dictates the strength of genetic 269 drift. Once the gatekeeper mutations are fixed, the phenotypic stability of the viral population is 270 maintained as a mutation-selection-drift balance and the range of phenotypic values explored by the 271 viral population is determined by the total number of infected individuals in the population. From an 272 epidemiological perspective, Sabin 2 reversion causes infectiousness and shedding duration to rapidly 273 increase within the first 200 days of vaccination and allow more individuals to become infected. Despite 274 the emergence of WPV-like viruses in our simulations, complete genetic reversion of Sabin 2 does not 275 guarantee a cVDPV2 outbreak. Whether these viruses cause a cVDPV2 outbreak requiring public health 276 intervention depends on population-level immunity and the average viral exposure dose per infectious 277 contact (4, 6, 22, 32).

278 The current strategies for controlling cVDPV2 involve implementing aggressive mOPV2 SIA 279 activities in outbreak response zones and neighboring regions, intensifying routine immunization in high-risk areas with inactivated polio vaccine (IPV), ensuring a sufficient supply of Sabin 2 OPV for future 280 281 eradication strategies, and identifying high cVDPV2 outbreak risk zones (33). Our work clearly shows 282 that even regions with historically high vaccination rates are prone to cVDPV2 outbreaks if sanitation is 283 poor. Evaluations of high cVDPV2 outbreak risk regions should include sanitation assessments and utilize 284 tools designed to measure fecal contamination for other fecal-oral pathogens such as E. coli (34). Prior 285 to mass immunization with OPV2, sanitation assessments should be made to assess the risk of a cVDPV2 286 outbreak in both the targeted intervention zone and in the surrounding regions. These assessments will 287 be useful for resource allocation and for determining the minimum coverage needed to prevent future 288 cVDPV2 outbreaks. Regions with poor sanitation will require aggressive, high-coverage SIA vaccination 289 campaigns to prevent seeding future cVDPV2 outbreaks.

290 Sanitation assessments will also help public health officials determine whether additional WASH 291 (water, sanitation, and hygiene) interventions are needed to supplement ongoing vaccination activity. 292 Our study reconfirms that there are sanitation regimes defined by high fecal oral doses that is 293 guaranteed to seed future cVDPV2 outbreaks (22), regardless of vaccination coverage. Although long-294 term investments in infrastructure are prohibitively expensive, relatively simple measures such as the 295 installation of sanitary latrines and drinking water tubewells have been effective at reducing fecal 296 contamination in Matlab, Bangladesh (35). Optimistically, short-term sanitation interventions may be 297 effective if implemented similarly to an emergency response campaign (36), especially if they are 298 targeted at vaccine recipients and their immediate household community members (21). These targeted, 299 short-term sanitation interventions could alleviate some of the challenges associated with non-300 compliance, long-term adherence failure, and poor implementation that reduce the efficacy of standard 301 WASH interventions (37, 38).

302	Our model lays the foundations for integrating population genetic theory and epidemiology to
303	study the evolutionary epidemiology dynamics of rapidly evolving infectious diseases. The success of our
304	framework hinges on an understanding of a pathogen's evolutionary trajectory as well as the initial and
305	ending phenotypic states. We anticipate our model will be extended to the novel OPV2 (nOPV2)
306	candidates (39) as more about their clinical phenotypes and molecular evolution are known. Depending
307	on how attenuated and evolutionarily stable the novel OPV2 candidates are relative to Sabin 2, mass
308	nOPV2 vaccination may reduce the need to also control sanitation levels. We also anticipate our model
309	will be useful for assessing the risks associated with the live-attenuated varicella zoster vaccines, which
310	also shows strong evidence of attenuation reversion conferred by a commonly accessed evolutionary
311	pathway (40).

312 Materials and Methods

313 Sequencing Data

314 We downloaded fasta files for the VP1 segments and whole genome sequences of Sabin 2 and 315 Sabin 2 derived genomes from Genbank. These samples were collected across 102 studies performed in 316 countries including Egypt, Madagascar, China, Nigeria, the United States, Israel, Switzerland, and the 317 Democratic Republic of Congo. Multiple sequence alignments were first generated using MUSCLE 318 (v3.8.31) (41). Sequences were compared to a known Sabin 2 sample (accession ID: AY184220) to 319 identify and remove insertions. Sequences with long internal gaps (>15 bases) and coverage < 30% 320 (percentage of called bases) were discarded. Coding sequence alignments from the whole genome 321 sequences were generated for each of the poliovirus coding regions by generating multiple sequence 322 alignments for each of the 15 translated protein coding sequences of the poliovirus genome. These 323 alignments were further filtered to remove samples with < 90% coverage.

324	A total of 177 whole genome sequences and 1,643 VP1 sequences were retained for analysis.
325	Samples were classified as Sabin 2, Sabin-Like, VDPV (vaccine-derived poliovirus), iVDPV
326	(immunodeficiency-related vaccine-derived poliovirus), cVDPV2 based on their original study
327	classifications. Viruses that displayed <1% VP1 nucleotide sequence difference from the parental Sabin 2
328	genome were classified as Sabin-lik2 and those with 1-15% nucleotide sequence difference were
329	classified as VDPV. VDVPVs isolated from immunodeficient individuals were classified as iVDPV while
330	samples with evidence of having originated from prior transmission are classified as cVDPV2. The whole
331	genome sample set also included the Lansing and MEF-1 laboratory strains as well as several engineered
332	Lansing strain derivatives. Accession numbers, classifications, and study origin for each sample are in
333	Supplemental File 1 and Supplemental File 2. FASTA files for the aligned VP1 and whole genome coding
334	sequences are available on the Github repository.
335	Coding sequence alignments were used to generate a phylogenetic tree using RAxML (v8.2.10)
336	with a general time reversable CAT (GTRCAT) model (42). Estimates of nonsynonymous and synonymous
337	mutation counts and dN/dS were based off the RAxML generated phylogenetic tree. Estimates of
338	nonsynonymous and synonymous mutation counts from the VP1 sequences were counted directly from
339	the sequence data. Nonsynonymous and synonymous mutation counts for codons with multiple
340	mutations were averaged across all possible, unweighted evolutionary paths.
341	Model Description

342 Defining Genotypes

343 Genotypes are defined relative to the Sabin-2 genome and defined by the reversion state of 344 three gatekeeper mutations (A481G, U2909C, and U398C), and the number of newly derived 345 nonsynonymous and synonymous mutations in the rest of the genome. The Sabin-2 genome is defined 346 as an array with 6 different mutation classes:

$$G_{S2} = [0, 0, 0, 0, 0, 0]$$

347	The first three are Boolean flags that indicate the allelic states of A481G, U2909C, and U398C (0 =
348	unreverted, 1 = reverted). The last three elements represent the total number of deleterious
349	nonsynonymous, neutral nonsynonymous, and synonymous mutations present in the genome. The
350	counts in the latter categories exclude the three gatekeeper mutations. Splitting nonsynonymous
351	mutations into neutral and deleterious simplifies the true distribution of fitness effects and was
352	necessary to reconcile phenotypic and molecular evolution (SI Appendix). These genotypes represent
353	the consensus sequence of fixed variants within vaccinated and infected individuals.
354	For evolved poliovirus strains, we use the notation:
	$G_{i,j,k,nonsyn_{del},nonsyn_{neutral},syn}$
355	
356	where <i>i</i> , <i>j</i> , and <i>k</i> are replaced with the allelic states of A481G, U209C, and U398C. $nonsyn_{neutral}$,
357	$nonsyn_{del}$, and syn are replaced with their respective counts or replaced with X if these mutation
358	classes are irrelevant. For example, $G_{0,0,0,0,0,0}$ is equivalent to the unmutated Sabin-2 vaccine strain (G_{S2})
359	and $G_{1,1,1,10,2,15}$ is a genotype where all three gatekeeper mutations have reverted and where 10
360	deleterious nonsynonymous, 2 neutral nonsynonymous, and 15 synonymous mutations have
361	accumulated.
362	Genomic evolution: Modeling Sabin 2 molecular evolution
363	Genomic evolution is modeled using intra-host substitution rates (λ), the fixation of newly
364	derived mutations within the host, for each mutation class ($\lambda_{A481G}, \lambda_{U2909C}, \lambda_{U398C}, \lambda_{syn},$

365 $\lambda_{nonsyn,del}, \lambda_{nonsyn,neutral}$). This substitution rate reflects the true de novo mutation rate, genetic drift,

366	and selection within the host. This simplification allows us to use a single consensus genome to
367	represent the fixed mutations present in the intra-host viral population. Each mutation class (the three
368	gatekeeper mutations, synonymous mutations, deleterious nonsynonymous mutations, and neutral
369	nonsynonymous mutations) is associated with a substitution rate that describes its expected fixation
370	time (Supplemental File 3).
371	To accommodate the effects of intra-host competition and recombination, deleterious
372	nonsynonymous mutation accumulation also depends on a recombination-like mechanism with rate
373	$\lambda_{recombination}$ that purges deleterious mutations from the genome (26, 28, 43). Intra-host substitution
374	rates for the gatekeeper mutations were used as described in (10) while λ_{syn} ,
375	$\lambda_{nonsyn,del},\lambda_{nonsyn,neutral}$, and $\lambda_{recombination}$ were calibrated to the whole genome sequences and
376	VP1 segments downloaded from Genbank. Only confirmed Sabin 2, Sabin-Like, VDPV, and cVDPV
377	samples were used for calibration. All other samples were excluded from calibration. Calibration details
378	are provided in the SI Appendix .
379	Upon vaccination with Sabin 2, fixation times for all mutation classes are calculated by drawing
380	from exponential distributions whose rate parameters are defined by the substitution rate of each
381	mutation class. For the three gatekeeper mutations, these fixation times determine the time to
382	reversion. For nonsynonymous and synonymous mutations, these fixation times determine the time to
383	the next substitution event. To prevent Mueller's Ratchet from resulting in infinite deleterious mutation
384	load, we also draw a time to the next "recombination" event from an exponential distribution defined
385	by $\lambda_{recombination}$. During each "recombination" event, the model draws a random number from a
386	discrete, uniform distribution ranging from zero to $n_{nonsyn,deleterious}$, the number of deleterious
387	nonsynonymous mutations in the genome, to determine the number of deleterious mutations to
388	remove. Conceptually, this represents purifying selection within the host and allows us to accommodate

the assumed increase in purifying selection as Sabin 2 reverts to cVDPV2. Pseudocode is provided in *Supplemental Figure 4*.

391

392 Genotype to Phenotype: Mapping molecular genetics to shedding duration and infectiousness

393 A core assumption of our model is that each of the three gatekeeper mutations contributes to 394 the final, WPV phenotype proportional to their relative substitution rates. This assumption is based in 395 part on evolutionary fitness landscape and adaptation theory, which posits that beneficial mutations of 396 large effect are more likely to be fixed early on when an organism is far the optimal fitness peak on a 397 simple, non-rugged fitness landscape (29, 44). By definition, attenuated Sabin 2 vaccine strains are far 398 from the optimal fitness peak for human infection and genetic reversion is the process of climbing the 399 fitness landscape to reach the optimal, WPV-like phenotype. Because of their fast substitution rate, we 400 attribute the bulk of phenotypic change to A481G, followed by U2909C, and to a lesser extent U398C. 401 The ranked ordering of phenotypic effect in our model is supported in the literature. A481G and U2909C 402 are consistently identified as the primary molecular determinants of reversion in *in vitro* and *in vivo* 403 studies (11–16). U398C is only occasionally identified by these studies but its recurrent fixation within 404 the first few months of transmission (9, 10) suggest its adaptive benefit may be too small to be assessed 405 in laboratory-based assays relative to A481G and U2909C.

Two epidemiologically relevant phenotypes were calculated for each infection based on its corresponding genotype: 1) shedding duration and 2) infectiousness. Both shedding duration and infectiousness are based on a previously described poliovirus dose-response model (22). Conceptually, the shedding duration is analogous to intra-host selection and infectiousness is analogous to inter-host selection. Details regarding model calibration are deferred to the **SI Appendix**.

411

We assume shedding duration follows a log-normal survival distribution with the form:

$$P\left(shedding \ at \ t \ \left|N_{ab_{pre}}; infected \ at \ t = 0\right)\right)$$

$$= \frac{1}{2} \left(1 - erf\left(\frac{ln(t) - (M_{g} - \log(\delta)\log_{2}(N_{ab_{pre}}))}{\sqrt{2}ln(S_{g})}\right)\right)$$
(1)

where $N_{ab_{pre}}$ is the pre-infection OPV-equivalent antibody titer (22). For each genotype, M_g and S_g are genome-specific parameters that influence the average shedding duration and its standard deviation. The mean of this log-normal distribution is defined by M_g $-\log(\delta)\log_2(N_{ab_{pre}})$ and its standard deviation defined by S_g.

$$M_g = \log(\mu_{S2}) + w_{shedding,g} \tag{2}$$

416

$$S_g = \sigma_{\sqrt{\left|1 + w_{shedding,g}\right|}} \tag{3}$$

417

$$w_{shedding,g} = 0 + s_{dur,A481G} * G_{A481G} + s_{dur,U2909C} * G_{U2909C} + s_{dur,U398C} * G_{U398C}$$
(4)
+ $s_{dur,nonsyn_{del}} * n_{nonsyn_{del}}$

418

419 where μ_{S2} is the average shedding duration of a completely unevolved Sabin 2 virus (G_{S2}) in

420 immunologically naive individuals ($N_{ab_{pre}} = 1$), σ the standard deviation in shedding duration for G_{S2} .

421 $w_{shedding,g}$ defines the shedding duration fitness of a strain, G_{A481G} , G_{U2909C} , and G_{U398C} refer to the

- 422 allelic status of the three gatekeeper mutations, and $s_{dur,A481G}$, $s_{dur,U2909C}$, $s_{dur,U398C}$ are selection
- 423 coefficients that describe the change in shedding duration conferred by each of these mutations. Note
- 424 that fitness is additive but in log space.

medRxiv preprint doi: https://doi.org/10.1101/2020.11.02.20224634; this version posted November 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Upon infection or vaccination, we randomly draw a shedding duration from a lognormal distribution with mean $M_g = \log(\delta) \log_2(N_{ab_{pre}})$ and standard deviation S_g . A core feature of our shedding duration model is that new gatekeeper mutations arising within the host extends shedding duration. If a new gatekeeper mutation is acquired, the shedding duration is extended:

$$Duration = Duration_{initial} * e^{S_{gateway} + Norm(0,\sigma) \sqrt{S_{gateway}}}$$
(5)

429

$$S_{gateway} \in \{s_{dur,A481G}, s_{dur,U2909C}, s_{dur,U398C}\}$$
(6)

430

431 where $D_{initial}$ is the shedding duration before acquisition of the gatekeeper mutation and $S_{gateway}$ is 432 the shedding duration selection coefficient for the gatekeeper mutation. Note that Duration_{initial} and the increase in shedding duration, $e^{S_{gateway} + Norm(0,\sigma)\sqrt{S_{gateway}}}$, are log-normally distributed and that 433 434 multiplying two, independent log-normal distributions results in a log-normal distribution whose mean 435 and variance are the sum of the mean and variances of the original distributions. As a result, shedding 436 duration is the summation of multiple, genome-specific shedding durations whose weights are timedependent and depend on the fixation of A481G, U2909C, U398C and the accumulation of 437 nonsynonymous mutations. 438

Infectiousness is defined by a beta-Poisson model that assumes a single infectious unit is
sufficient to start an infection and that multiple infectious units contribute independently to the
probability of infection:

$$P(infection|dose, N_{ab}) = 1 - \left(1 + \frac{dose}{\beta_g}\right)^{-\alpha(N_{ab})^{-\gamma}}$$
(7)

443 where α and β_g are parameters for a beta-Poisson function, dose is the viral exposure dose, and γ 444 captures the reduction in shedding probability with increasing immunity. Altering the β parameter 445 shifts the beta-poisson function along the x-axis (dose) and altering the α parameter changes its slope. 446 Differences in infectiousness between Sabin 2 strains and WPV can be modeled using the same α but 447 with modified β parameters (22). We interpret the β parameter as a measurement of strain infectivity 448 and define β_q as:

449

$$\beta_{g} = \frac{\beta}{\left(1 + s_{inf,A481G}\right)^{G_{A481G}} \left(1 + s_{inf,U2909C}\right)^{G_{U2909C}} \left(1 + s_{inf,U398C}\right)^{G_{U398C}} \left(1 + s_{inf,nonsyn_{del}}\right)^{n_{nonsyn_{del}}}}$$
(8)

- 450
- 451

452 where β is the strain infectivity parameter for Sabin 2 (22) (assuming no evolution), $s_{inf,A481G}$, $s_{inf,U2909C}$, $s_{inf,U398C}$, $s_{inf,nonsyn_{del}}$ are selection coefficients denoting the change in infectiousness 453 454 conferred by each of the gatekeeper mutations, and $n_{nonsyn_{del}}$ are the number of nonsynonymous 455 mutations in the genome. Parameter estimates were obtained by comparing the CCID50 between Sabin 456 2 and WPV (SI Appendix). The inferred selection coefficients for the three gatekeeper mutations are 457 positive (increases infectiousness) while the selection coefficient for deleterious nonsynonymous 458 mutations was negative (decreases infectiousness). Infectiousness is calculated only at the onset of 459 either vaccination or infection.

460

461 Acknowledgements

- 462 We acknowledge all members of the Institute for Disease Modeling, Global Good, and the Bill and
- 463 Melinda Gates Foundation for their useful discussion and input. We also acknowledge Adam Lauring and
- 464 Andrew Valesano for early manuscript edits and comments.

465 Funding

- 466 Funding was provided by Bill and Melinda Gates through the Global Good Fund. Funders had no role in
- the study design, data collection, analysis, interpretation, or writing of the manuscript. The
- 468 corresponding author had full access to all the data in our study and had final responsibility for the
- decision to submit for publication.

470 Data Availability

- 471 Data and code will be made publicly available at
- 472 <u>https://github.com/InstituteforDiseaseModeling/MultiscaleModeling/tree/evo_epistasis</u> upon
- 473 publication.

474 **Declaration of Interests**

- 475 The authors declare no competing interests during the study. WW, JG, and MF were employed by the
- 476 funders through the Bill and Melinda Gates Foundation after study completion.

477 References

- 478 1. F. Khan, et al., rogress Toward Polio Eradication Worldwide, January 2016–March 2018.
- 479 *MMWR Morb Mortal Wkly Rep 2019*, 524–528 (2018).
- 480 2. A. S. Bandyopadhyay, J. Garon, K. Seib, W. A. Orenstein, Polio vaccination: past, present and
 481 future. *Future Microbiol.* 10, 791–808 (2015).
- 482 3. H. E. Jenkins, et al., Implications of a Circulating Vaccine-Derived Poliovirus in Nigeria. N. Engl. J.

483 *Med.* **362**, 2360–2369 (2010).

- 484 4. J. Jorba, *et al.*, Update on Vaccine-Derived Poliovirus Outbreaks Worldwide, January 2018–
 485 June 2019. *Morb. Mortal. Wkly. Rep.*, 1024–1028 (2049).
- 486 5. M. Alleman, et al., Update on Vaccine-Derived Poliovirus Outbreaks Worldwide July 2019-
- 487 February 2020. MMWR Morb Mortal Wkly Re, 89–495 (2020).
- 488 6. G. R. Macklin, *et al.*, Evolving epidemiology of poliovirus serotype 2 following withdrawal of the
 489 type 2 oral poliovirus vaccine. *Science (80-.).*, eaba1238 (2020).
- 490 7. J. W. Almond, The attenuation of poliovirus neurovirulence. *Annu. Rev. Microbiol.* 41, 153–180
 491 (1987).
- 492 8. A. B. Sabin, L. R. Boulger, History of Sabin attenuated poliovirus oral live vaccine strains. *J. Biol.*493 *Stand.* 1, 115–118 (1973).
- 494 9. A. Stern, *et al.*, The Evolutionary Pathway to Virulence of an RNA Virus. *Cell* 169, 35-46.e19
 495 (2017).
- 496 10. M. Famulare, *et al.*, Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like
 497 Poliovirus Isolates in Nigeria. *J. Virol.* **90**, 317–331 (2015).
- 498 11. O. M. Kew, R. W. Sutter, E. M. de Gourville, W. R. Dowdle, M. A. Pallansch, Vaccine-derived
 499 polioviruses and the endgame strategy for global polio eradication. *Annu. Rev. Microbiol.* 59,
 500 587–635 (2005).
- 12. R. J Duintjer Tebbens, *et al.*, Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling
 the Risks of Circulating Vaccine-Derived Polioviruses (cVDPVs). *Risk Anal.* 23 (2013).
- 503 13. A. R. Muzychenko, et al., Coupled mutations in the 5'-untranslated region of the Sabin poliovirus

- 504 strains during in vivo passages: structural and functional implications. *Virus Res.* **21**, 111–122
- 505 (1991).
- 506 14. K. M. S. de M. Cassemiro, et al., Molecular and Phenotypic Characterization of a Highly Evolved
- 507 Type 2 Vaccine-Derived Poliovirus Isolated from Seawater in Brazil, 2014. *PLoS One* **11**,
- 508 e0152251-e0152251 (2016).
- 509 15. E. A. Simoes, P. Sarnow, An RNA hairpin at the extreme 5' end of the poliovirus RNA
- 510 genome modulates viral translation in human cells. J. Virol. 65, 913 LP 921 (1991).
- 511 16. R. B. Ren, E. G. Moss, V. R. Racaniello, Identification of two determinants that attenuate vaccine-
- 512 related type 2 poliovirus. J. Virol. 65, 1377–1382 (1991).
- 513 17. H. Asghar, *et al.*, Environmental Surveillance for Polioviruses in the Global Polio Eradication
 514 Initiative. *J. Infect. Dis.* 210, S294–S303 (2014).
- 515 18. R. Abraham, P. Minor, G. Dunn, J. F. Modlin, P. L. Ogra, Shedding of Virulent Poliovirus Revertants
- 516 during Immunization with Oral Poliovirus Vaccine after Prior Immunization with Inactivated Polio
- 517 Vaccine. J. Infect. Dis. **168**, 1105–1109 (1993).
- 518 19. I. M. Blake, *et al.*, Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine.
 519 *N. Engl. J. Med.* **379**, 834–845 (2018).
- 520 20. M. Taniuchi, et al., Community transmission of type 2 poliovirus after cessation of trivalent oral
- 521 polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study. *Lancet*.
- 522 Infect. Dis. **17**, 1069–1079 (2017).
- 523 21. M. Famulare, *et al.*, Community structure mediates Sabin 2 polio vaccine virus transmission.
- 524 *medRxiv*, 2020.07.01.20144501 (2020).

525	22.	M. Famulare, C. Selinger, K. A. McCarthy, P. A. Eckhoff, G. Chabot-Couture, Assessing the stability
526		of polio eradication after the withdrawal of oral polio vaccine. PLOS Biol. 16, e2002468 (2018).
527	23.	S. Wassilak, et al., Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and
528		widespread circulation in an underimmunized population. J. Infect. Dis. 203, 898–909 (2011).
529	24.	K. M. Thompson, R. J. Duintjer Tebbens, Modeling the dynamics of oral poliovirus vaccine
530		cessation. J. Infect. Dis. 210 Suppl , S475-84 (2014).
531	25.	A. L. Hughes, Near-Neutrality: the Leading Edge of the Neutral Theory of Molecular Evolution.
532		Ann N Y Acad Sci 1133 , 162–179 (2008).
533	26.	L. Chao, Fitness of RNA virus decreased by Muller's ratchet. <i>Nature</i> 348 , 454–455 (1990).
534	27.	T. Leitner, The Puzzle of HIV Neutral and Selective Evolution. <i>Mol. Biol. Evol.</i> 35 , 1355–1358
535		(2018).
536	28.	Y. Xiao, et al., RNA Recombination Enhances Adaptability and Is Required for Virus Spread and
537		Virulence. <i>Cell Host Microbe</i> 19 , 493–503 (2016).
538	29.	O. Tenaillon, The Utility of Fisher's Geometric Model in Evolutionary Genetics. Annu. Rev. Ecol.
539		<i>Evol. Syst.</i> 45 , 179–201 (2014).
540	30.	D. L. Hartl, C. H. Taubes, Towards a theory of evolutionary adaptation. <i>Genetica</i> 102–103, 525–
541		533 (1998).
542	31.	J. T. McCrone, et al., Stochastic processes constrain the within and between host evolution of
543		influenza virus. <i>Elife</i> 7 , e35962 (2018).
544	32.	K. A. McCarthy, G. Chabot-Couture, M. Famulare, H. M. Lyons, L. D. Mercer, The risk of type 2
545		oral polio vaccine use in post-cessation outbreak response. BMC Med. 15, 175 (2017).
		25

546	33.	Geneva: World Health Organization, "Strategy for the Response to Type 2 Circulating Vaccine-
547		Derived Poliovirus 2020–2021: An addendum to the Polio Endgame Strategy 2019-2023" (2020).
548	34.	Y. Wang, et al., Multipathway Quantitative Assessment of Exposure to Fecal Contamination for
549		Young Children in Low-Income Urban Environments in Accra, Ghana: The SaniPath Analytical
550		Approach. <i>Am. J. Trop. Med. Hyg.</i> 97 , 1009–1019 (2017).
551	35.	K. Zaman, et al., Can cholera 'hotspots' be converted to cholera 'coldspots' in cholera endemic
552		countries? The Matlab, Bangladesh experience. Int. J. Infect. Dis. 95 , 28–31 (2020).
553	36.	T. Yates, J. Allen, M. L. Joseph, D. Lantagne, "Short-term WASH interventions in emergency
554		responses in low- and middle-income countries" (2017).
555	37.	A. Ramesh, K. Blanchet, J. H. J. Ensink, B. Roberts, Evidence on the Effectiveness of Water,
556		Sanitation, and Hygiene (WASH) Interventions on Health Outcomes in Humanitarian Crises: A
557		Systematic Review. <i>PLoS One</i> 10 , e0124688–e0124688 (2015).
558	38.	M. Wolfe, M. Kaur, T. Yates, M. Woodin, D. Lantagne, A Systematic Review and Meta-Analysis of
559		the Association between Water, Sanitation, and Hygiene Exposures and Cholera in Case–Control
560		Studies. <i>Am. J. Trop. Med. Hyg.</i> 99 , 534–545 (2018).
561	39.	P. Van Damme, et al., The safety and immunogenicity of two novel live attenuated monovalent
562		(serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1
563		study. <i>Lancet</i> 394 , 148–158 (2019).
564	40.	J. Breuer, Molecular Genetic Insights Into Varicella Zoster Virus (VZV), the vOka Vaccine Strain,
565		and the Pathogenesis of Latency and Reactivation. J. Infect. Dis. 218, S75–S80 (2018).
566	/11	R. C. Edgar, MUSCLE: a multiple sequence alignment method with reduced time and space

K. C. Edgar, MUSCLE: a multiple sequence alignment method with reduced time and space
 complexity. *BMC Bioinformatics* 5, 113 (2004).

- 568 42. A. Stamatakis, RAxML version 8: a tool for phylogenetic analysis and post-analysis of large
- 569 phylogenies. *Bioinformatics* **30**, 1312–1313 (2014).
- 570 43. M. Bessaud, M.-L. Joffret, B. Blondel, F. Delpeyroux, Exchanges of genomic domains between
- 571 poliovirus and other cocirculating species C enteroviruses reveal a high degree of plasticity. *Sci.*
- 572 *Rep.* **6**, 38831 (2016).
- 573 44. E. Svensson, R. Calsbeek, *The Adaptive Landscape in Evolutionary Biology* (OUP Oxford, 2012).
- 574
- 575
- 576
- 577
- 578
- 579

580





582 Figure 1 Sabin 2 transmission and reversion schematic A) Multiscale epidemiology model. Individuals 583 are organized into a series of nested, demographic scales defined by households, baris/neighborhoods, 584 and villages that together define the greater region. The *bari* is an intergenerational living arrangement 585 of closely related individuals specific to Matlab, the study population the epidemiology model was 586 calibrated to. Conceptually, it is analogous to a neighborhood. Infectious contacts occur at different 587 rates to individuals in each of these demographic scales. During each infectious contact, infected 588 individuals transmit a viral dose that depends on their individual viral shedding concentration and the 589 average fecal oral dose per contact in the population. B) Sabin 2 reversion model. Sabin 2 evolution is 590 modeled as a population of competing viral lineages whose average phenotypic end state distribution is 591 identical to that of WPV. Reversion is driven by the acquisition of three gatekeeper mutations (A481G, 592 U2909C, U398C) and the acquisition of deleterious mutations introduced through mutation and purged 593 through selection.



596	Figure 2 Molecular evolution. A) Phylogenetic tree based on the nonsynonymous mutations from the
597	177 whole genome sequences used to calibrate our model. Samples were categorized as Sabin 2, Sabin-
598	Like, vaccine-derived poliovirus isolated from immunocompromised individuals (iVDPV), vaccine-derived
599	poliovirus (VDPV), and cVDPV2. The other category includes the Lansing and MEF-1 laboratory strains as
600	well as several engineered strains derived from the Lansing strain. Samples classified as iVDPV or
601	"other" were excluded from model calibration. ${f B}$) Simulated genome-wide nonsynonymous mutation
602	accumulation over time (orange) compared against those observed in the Sabin 2, Sabin-Like, VDPV, and
603	cVDPV2 whole genome sequences. C) Simulated (<i>pink</i>) VP1 mutation (synonymous and
604	nonsynonymous) accumulation over time compared against the mutation counts observed in 1,643 VP1
605	segments. D) The ratio of nonsynonymous and synonymous mutations throughout the genome over
606	time. E) Simulated genome-wide nonsynonymous counts partitioned into deleterious (brown) and
607	neutral (grey). Across all figures, the solid line is the mean simulation outcome and the shaded area
608	marks the boundaries of the middle 95%. Empirical data is represented by points and colored according
609	to the legend in panel A . Time was calculated by dividing the number of synonymous mutations per
610	sample by the synonymous substitution rate (3.16E-05 substitutions/bp/day). The insets in B,C, and E
611	are close ups of the first year of evolution to better show short-term evolution dynamics.



614 Figure 3 Phenotypic Evolution A) Cumulative density reversion probability functions for the three 615 gatekeeper mutations. The solid line is the mean and the shading the 95% confidence interval. B) 616 Shedding duration profile of immunologically naïve individuals infected with Sabin 2, WPV/cVDPV2, and 617 three different intermediate viral genotypes. The dotted lines are the shedding durations of the initial viral genotype assuming no further reversion or evolution. The solid line are the shedding durations of 618 619 each viral genotype where the reversion of new gatekeeper mutations extends the current shedding 620 duration. Nonsynonymous mutations have no discernable phenotypic effect with regards to shedding 621 duration. C and D) Viral infectiousness. Each curve shows strain-specific probability of infection given a 622 single CCID50 dose plotted against immunity. Panel C shows infectiousness following the acquisition of 623 each of the three gatekeeper mutations. Panel **D** emphasizes the role of deleterious nonsynonymous

624 mutation and shows the infection probability of different viral genotypes with all gatekeeper mutations





Figure 4 Evo-epidemiological dynamics following a mass vaccination campaign targeting 10% of children under five, five years post-vaccination cessation in Matlab, Bangladesh. Simulations assume 10x the fecal oral dose in Matlab to ensure stable transmission and conditioned on stable, endemic transmission for at least three years. **A**) Total number of infected individuals over time. Solid line indicates the mean and the shading the boundaries of the middle 95% from 200 simulations **B**) Longitudinal immune

profiles for individuals with low immunity (*red*, antibody titer < 8), intermediate immunity (*light blue*,
antibody titer > 8 and < 256), and high immunity (*dark blue*, antibody titer > 256). C) Shedding duration
evolution in naïve individuals over time. D) Viral infectiousness evolution over time. For panels B-D, the
solid line denotes the simulated average and the boundaries the 95% confidence interval around the
mean. For panels C and D, the dashed black line indicates the average WPV phenotype.

638



640 **Figure 5 cVDPV2 outbreak risk**. cVDPV2 emergence after a mOPV2 vaccination campaign (A-C) or

641 importation of a single infant immunized with Sabin 2 (**D-F**) occurring after up to five years of

vaccination cessation with fecal-oral doses equivalent to (A/D), five times greater (B/E), and 10 times

643 greater (C/F) than that inferred for Matlab during an mOPV2 clinical trial.



Supplemental Figure 1 dN/dS ratios for Sabin 2-like, cVDPV2, WPV, and iVDPVs.





Supplemental Figure 2 Simulated evolutionary and epidemiology dynamics following a mass
vaccination campaign targeting 10% of children under five, five years post-vaccination cessation in
Matlab, Bangladesh, conditioned on epidemic extinction within the first three years of transmission. A)
Total number of infected individuals over time B) Infectiousness represented as the probability of
infecting an immunologically naïve individual given single CCID50 unit dose. C) Shedding duration in
immunologically naïve individuals. Each line represents a different simulation outcome.





Supplemental Figure 3 The variance of the expected mean (*black*) for shedding duration (A) and
infectiousness (B) compared against infection count (*orange*). The solid orange line is the mean and

shading the boundaries of the middle 95 percentile from 200 simulations and identical to **Figure 4A**.

Algorithm 1: Sabin 2 Intra-Host Molecular evolution Initialization:

Step 1: Set reversion times for unreverted gateway mutations for mutation in A481G, U2909C, U398C do if not reverted then | Draw reversion time, $t_{reversion_{mutation}}$, from Exponential($\lambda_{mutation}$) end end

Step 2: Set substitution times for non-gateway mutations for mutation in nonsyn_{del}, nonsyn_{neutral}, syn do | Draw substitution time, $t_{subtitution_{mutation}}$, from Exponential($\lambda_{mutation}$) end

Step 3: Set recombination time Draw recombination time, t_{recomb} , from Exponential(λ_{recomb})

Intra-host Evolution:

```
while t_{infection} < t_{shed} do
    Step 1: Check if unreverted gateway mutations will revert
     for mutation in A481G, U2909C, U398C do
        if t_{infection} = t_{reversion_{mutation}} then
           Revert mutation
        end
    end
    Step 2: Check if new non-gateway mutations are fixed
     for mutation in nonsyn_{del}, nonsyn_{neutral}, syn do
        if t_{infection} = t_{reversion_{mutation}} then
            Increase mutation count, n_{mutation}, by 1
             Draw a new t_{mutation} from Exponential(\lambda_{mutation})
    end
    Step 3: Check if deleterious nonsynonymous mutations are purged
     if t_{infection} = t_{recomb} then
        Draw X from Uniform(0, n_{nonsyn_{del}})
         Subtract X from the deleterious nonsynonymous mutation count, n_{nonsyn_{del}}
        Draw a new t_{recomb} from Exponential(\lambda_{recomb})
end
```

664

Genotype	Proportion	Expected Shedding Duration
Sabin 2 (no reversions)	0.076 (0.059, 0.093)	14.39 (14.08, 14.69)
A481G only	0.186 (0.162, 0.211)	25.46 (24.71, 26.24)
U2909C only	0.024 (0.014, 0.034)	20.39 (19.85, 20.92)
U398C only	0.01 (0.004, 0.016)	18.98 (18.52, 19.47)
A481G + U398C	0.075 (0.059, 0.091)	33.53 (32.46, 34.62)
U398C + U2909C	0.005 (0.001, 0.01)	26.90 (26.10, 27.72)
A481G + U2909C	0.273 (0.247, 0.300)	36.08 (34.93, 37.26)
A481G + U2909C + U398C	0.352 (0.325, 0.382)	47.51 (45.93, 49.174)

665

Supplemental Table 1 Final viral genotypes in primary vaccine recipients and the expected shedding
durations of individuals infected with these genotypes, assuming no further reversion. Bootstrapped
confidence interval for the mean were calculated from 1000 simulated primary vaccinations, repeated
1000 times. Shedding durations are reported in days. Sabin 2 in this table is defined as a viral genotype
with zero gatekeeper reversions.

671

672 **Supplemental File 1** Accession numbers and study origins of the whole genome sequences

673 Supplemental File 2 Accession numbers and study origins of the VP1 segments